| |
PFS
|
OS
|
|---|
| |
Hazard ratio
|
95% CI
|
P
|
Hazard ratio
|
95% CI
|
P
|
|---|
|
Baseline CTC status (CTC
BL
)
|
|
< 5 CTC (CTCBL-)
|
1.00
| | |
1.00
| | |
|
≥ 5 CTC (CTCBL+)
|
1.55
|
1.19–2.01
|
0.001
|
2.79
|
2.04–5.63
|
< 0.001
|
|
Age at inclusion
|
|
Per year
|
0.99
|
0.98–1.00
|
0.207
|
1.00
|
0.99–1.01
|
0.938
|
|
Number of metastatic sites
|
|
One site
|
1.00
| | |
1.00
| | |
|
Multiple sites
|
0.97
|
0.66–1.43
|
0.892
|
0.71
|
0.41–1.23
|
0.227
|
|
Site of metastasis
|
|
Bone
|
1.00
| | |
1.00
| | |
|
Visceral/local
|
0.98
|
0.67–1.46
|
0.939
|
1.75
|
1.00–3.01
|
0.052
|
|
Both
|
1.07
|
0.71–1.63
|
0.739
|
2.55
|
1.41–4.60
|
0.002
|
|
Line of therapy
|
|
1
|
1.00
| | |
1.00
| | |
|
2
|
1.35
|
0.93–1.95
|
0.113
|
1.45
|
0.92–2.28
|
0.112
|
|
≥ 3
|
1.91
|
1.40–2.59
|
< 0.001
|
2.01
|
1.37–2.96
|
< 0.001
|
|
Molecular Subtypes
|
|
HR+/HER2-
|
1.00
|
°
| |
1.00
| | |
|
HER2+
|
1.10
|
0.79–1.52
|
0.577
|
1.09
|
0.72–1.63
|
0.695
|
|
TNBC
|
1.92
|
1.36–2.71
|
< 0.001
|
2.86
|
1.91–4.27
|
< 0.001
|
- Bold P values indicate statistical significance.
- HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.
